Tekla Life Sciences Stock Performance
| HQL Stock | USD 13.79 0.04 0.29% |
The entity has a beta of 0.73, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tekla Life's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tekla Life is expected to be smaller as well. At this point, Tekla Life Sciences has a negative expected return of -0.0848%. Please make sure to validate Tekla Life's value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Tekla Life Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Tekla Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Tekla Life is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 1.96 | Five Day Return (1.26) | Year To Date Return 2.4 | Ten Year Return (42.82) | All Time Return (6.27) |
Forward Dividend Yield 0.145 | Payout Ratio 0.9925 | Forward Dividend Rate 2 | Dividend Date 2018-12-31 | Ex Dividend Date 2024-11-21 |
1 | Acquisition by Saba Capital Management, L.p. of 33357 shares of Tekla Life at 13.5 subject to Rule 16b-3 | 09/06/2024 |
| Tekla Life dividend paid on 30th of September 2024 | 09/30/2024 |
2 | abrdn Life Sciences Investors declares 0.50 dividend | 11/11/2024 |
| Begin Period Cash Flow | 445.00 |
Tekla |
Tekla Life Relative Risk vs. Return Landscape
If you would invest 1,461 in Tekla Life Sciences on August 28, 2024 and sell it today you would lose (82.00) from holding Tekla Life Sciences or give up 5.61% of portfolio value over 90 days. Tekla Life Sciences is generating negative expected returns assuming volatility of 1.1785% on return distribution over 90 days investment horizon. In other words, 10% of stocks are less volatile than Tekla, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Tekla Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tekla Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tekla Life Sciences, and traders can use it to determine the average amount a Tekla Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0719
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HQL |
Estimated Market Risk
| 1.18 actual daily | 10 90% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tekla Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tekla Life by adding Tekla Life to a well-diversified portfolio.
Tekla Life Fundamentals Growth
Tekla Stock prices reflect investors' perceptions of the future prospects and financial health of Tekla Life, and Tekla Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tekla Stock performance.
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 1.56 % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 370.8 M | ||||
| Shares Outstanding | 27.35 M | ||||
| Price To Earning | 2.84 X | ||||
| Price To Book | 0.86 X | ||||
| Price To Sales | 107.36 X | ||||
| Revenue | 23.52 M | ||||
| Gross Profit | 3.02 M | ||||
| EBITDA | 22.35 M | ||||
| Net Income | 22.35 M | ||||
| Cash And Equivalents | 292.4 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 666.96 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 16.13 X | ||||
| Cash Flow From Operations | (12.8 M) | ||||
| Earnings Per Share | 1.34 X | ||||
| Market Capitalization | 377.16 M | ||||
| Total Asset | 402.6 M | ||||
| Retained Earnings | (1.48 M) | ||||
About Tekla Life Performance
By examining Tekla Life's fundamental ratios, stakeholders can obtain critical insights into Tekla Life's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Tekla Life is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 675 | |
| Return On Tangible Assets | 0.05 | 0.04 | |
| Return On Capital Employed | (0.01) | (0.02) | |
| Return On Assets | 0.05 | 0.04 | |
| Return On Equity | 0.05 | 0.04 |
Things to note about Tekla Life Sciences performance evaluation
Checking the ongoing alerts about Tekla Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tekla Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tekla Life Sciences generated a negative expected return over the last 90 days | |
| Tekla Life Sciences has high likelihood to experience some financial distress in the next 2 years | |
| Tekla Life Sciences has about 292.4 K in cash with (12.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| On 30th of September 2024 Tekla Life paid $ 0.49 per share dividend to its current shareholders | |
| Latest headline from seekingalpha.com: abrdn Life Sciences Investors declares 0.50 dividend |
- Analyzing Tekla Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tekla Life's stock is overvalued or undervalued compared to its peers.
- Examining Tekla Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tekla Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tekla Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tekla Life's stock. These opinions can provide insight into Tekla Life's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.